Changes

Jump to navigation Jump to search
8 bytes removed ,  00:28, May 16, 2023
Spelling, grammar, and general cleanup, typos fixed: Covid-19 → COVID-19 (3)
Line 1: Line 1: −
'''Ivermectin''' is an off-[[patent]] (generic), inexpensive medication that is widely considered to be an effective treatment for [[COVID-19]] as suggested by numerous, constantly updated studies compiled online and by peer-reviewed studies worldwide.<ref>https://ivmmeta.com/</ref>  The Chairman of the [[Japan|Japanese]] medical association announced in late August 2021 that physicians should use ivermectin to treat Covid-19, but it continues to be suppressed by [[liberal]]s in the [[United States]].  "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19," according to a study published in a journal posted by the [[NIH]]'s National Library of Medicine.<ref>https://pubmed.ncbi.nlm.nih.gov/33278625/</ref>  Its beneficial biological mechanism has been published by an NIH peer-reviewed article.<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996102/</ref>
+
'''Ivermectin''' is an off-[[patent]] (generic), inexpensive medication that is widely considered to be an effective treatment for [[COVID-19]] as suggested by numerous, constantly updated studies compiled online and by peer-reviewed studies worldwide.<ref>https://ivmmeta.com/</ref>  The Chairman of the [[Japan]]ese medical association announced in late August 2021 that physicians should use ivermectin to treat COVID-19, but it continues to be suppressed by [[liberal]]s in the [[United States]].  "A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19," according to a study published in a journal posted by the [[NIH]]'s National Library of Medicine.<ref>https://pubmed.ncbi.nlm.nih.gov/33278625/</ref>  Its beneficial biological mechanism has been published by an NIH peer-reviewed article.<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996102/</ref>
    
Litigation by [[Judicial Watch]] uncovered that [[British]] physicians scientists recommended ivermectin to treat and prevent [[COVID-19]],<ref>https://www.judicialwatch.org/ivermectin-for-treatment-of-covid/</ref> yet this was withheld from the public during the pandemic.
 
Litigation by [[Judicial Watch]] uncovered that [[British]] physicians scientists recommended ivermectin to treat and prevent [[COVID-19]],<ref>https://www.judicialwatch.org/ivermectin-for-treatment-of-covid/</ref> yet this was withheld from the public during the pandemic.
Line 27: Line 27:     
==Randomized Trial Negative Results==
 
==Randomized Trial Negative Results==
−
Double-blind, randomized trial that included 476 patients and conducted at a single site in Cali, Colombia, did not support the use of ivermectin for treatment of mild COVID-19. Larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes. <ref>https://jamanetwork.com/journals/jama/fullarticle/2777389</ref>
+
Double-blind, randomized trial that included 476 patients and conducted at a single site in Cali, Colombia, did not support the use of ivermectin for treatment of mild COVID-19. Larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.<ref>https://jamanetwork.com/journals/jama/fullarticle/2777389</ref>
    
==University of Oxford Study==
 
==University of Oxford Study==
−
The University of Oxford in the UK has added ivermectin to the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE) study for the treatment of Covid-19. In small pilot studies, early use of ivermectin was able to lower viral load and the duration of symptoms in some mild Covid-19 patients. <ref>https://www.clinicaltrialsarena.com/news/ivermectin-principle-trial-covid/</ref>
+
The University of Oxford in the UK has added ivermectin to the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE) study for the treatment of COVID-19. In small pilot studies, early use of ivermectin was able to lower viral load and the duration of symptoms in some mild COVID-19 patients.<ref>https://www.clinicaltrialsarena.com/news/ivermectin-principle-trial-covid/</ref>
    
== See also ==
 
== See also ==
Block, SkipCaptcha, apieditor, Automoderated users, Bots, edit, ratelimit-exempt
58,183

edits

Navigation menu